Gene sequence constructs for the treatment of central nervous system disorders
Patent Information
- Application Number
- JP2020567122
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-05
- Filing Date
- 2019-05-31
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2039-05-31
AI Technical Summary
Conventional gene therapy methods for Parkinson's disease face challenges in achieving balanced expression of dopamine synthesis genes, such as tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), and aromatic amino acid decarboxylase (AADC), often resulting in imbalanced expression and reduced efficiency when using internal ribosome entry sites (IRES) or fusion proteins.
The use of an automated processing unit (APU) comprising N-terminal and C-terminal domains, such as Intein and 2A peptides, to combine and express these enzymes independently within a viral vector, specifically using lentiviral or adeno-associated viral vectors, ensuring efficient and balanced expression of TH, GCH1, and AADC for dopamine synthesis.
This approach enhances the balance of target protein expression, increases dopamine synthesis, and improves the therapeutic efficacy for Parkinson's disease by stabilizing the expression of TH, GCH1, and AADC, thereby improving treatment outcomes.
Abstract
Description
[Technology Field]
[0001] The present invention relates to the field of gene therapy, and more specifically to a gene sequence construct for the treatment of central nervous system diseases, wherein the gene sequence construct may be used for the prevention or treatment of Parkinson's disease, Alzheimer's disease, and other neurodegenerative diseases. [Background technology]
[0002] Parkinson's disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra, leading to a decrease in midbrain dopamine levels. Parkinson's disease affects approximately 1% of the world's population aged 55 and older, and the number of patients continues to increase with the aging of society. The common treatment for Parkinson's disease is oral administration of levodopa, a dopamine precursor, which can alleviate symptoms to some extent. However, as the disease progresses, levodopa treatment becomes unsatisfactory.
[0003] Gene therapy offers unique advantages in treating Parkinson's disease. By targeting and transmitting the dopamine synthesis gene to the striatum, dopamine can be synthesized and released within the striatum, thereby making the treatment of Parkinson's disease more effective. Tyrosine is catalyzed by tyrosine hydroxylase (TH) to synthesize levodopa, and then aromatic amino acid decarboxylase (AADC) converts levodopa to dopamine. TH requires tetrahydrobiopterin as a coenzyme, and since tetrahydrobiopterin is synthesized by GTP-cyclohydrolase 1 (GCH1), dopamine can be efficiently synthesized by expressing TH, AADC, and GCH1 (Azzouz M et al., 2002. J Neurosci. 22(23):10302-12. J Neurosci B et al., 2009. Sci Transl Med. 1(2):2).
[0004] In 2014, lentiviral vectors based on equine infectious anemia virus (EIAV) containing three major dopamine synthase enzymes linked at two internal ribosome entry sites (IRESs) showed promising results in Phase I / II clinical trials (Palfi S et al., 2014. Lancet. 383(9923):1138-46.). However, this method has many problems, such as consistently unbalanced expression occurring when expressing three genes at IRESs. Therefore, Stewart HJ et al. replaced the IRES elements with linker peptides to generate fusion proteins containing two or more of the three enzyme activities necessary for dopamine synthesis (stewart HJ et al., 2016. Hum Gene Ther Clin Dev. 27(3):100-10.). However, in its natural state, the three proteins TH, AADC, and GCH1 are expressed as independent proteins, and fusion proteins may affect the efficiency of dopamine synthesis. Therefore, finding new protein-binding expression methods, selecting appropriate vectors, introducing them into target cells, and efficiently expressing them remains a problem to be solved in the treatment of Parkinson's disease. [Overview of the project] [Problems that the invention aims to solve]
[0005] This invention aims to address the shortcomings of conventional therapeutic techniques by enabling the construction of a vector through auto-processing, along with the expression of tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid dopa decarboxylase (AADC), and nerve growth factors. These proteins are then bound together by an auto-processing unit (APU), and introduced into target cells via a viral vector. Ultimately, the goal is to generate highly expressed, independently functioning tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), and aromatic amino acid dopa decarboxylase (AADC) for the treatment of Parkinson's disease. [Means for solving the problem]
[0006] The present invention comprises the following: a gene sequence construct for the treatment of central nervous system disorders, wherein the construct is a nucleotide sequence related to the treatment of central nervous system disorders, which is conjugated by an automated processing unit (APU). Preferably, the nucleotide sequences related to the treatment of central nervous system diseases in the gene sequence construct for the treatment of central nervous system diseases are two or more selected from tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid dopa decarboxylase (AADC), and nervous system growth factor nucleotide sequences. At least two of the nucleotide sequences are joined by an automated processing unit (APU), the automated processing unit (APU) includes an N-terminal automated processing structure domain and / or a C-terminal automated processing structure domain. Preferably, the nerve growth factors include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), nerve growth factor-3 (NT-3), nerve growth factor-4 / 5 (NT-4 / 5), nerve growth factor-6 (NT-6), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), and the GDNF molecular family (naturally occurring analogs of GDNF, nerve rank proteins, percephin, and artemin). Preferably, the gene sequence construct for the treatment of central nervous system disorders comprises tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), and aromatic amino acid dopa decarboxylase (AADC). At least two of the aforementioned nucleotide sequences are combined by an automated processing unit (APU). Preferably, the N-terminal autoprocessing structure domain includes intein, a type B bacterial intein-like structure domain (BIL), a furin sequence, and derivatives thereof. Preferably, the C-terminal automated processing structure domain comprises a 2A peptide or a 2A-like peptide. Preferably, the 2A peptide or 2A-like peptide in the gene sequence construct for the treatment of central nervous system diseases includes a 2A peptide derived from foot-and-mouth disease virus (F2A), a 2A peptide derived from porcine zieshen virus (P2A), a 2A peptide derived from insect virus (T2A), and a 2A peptide derived from equine rhinitis virus (E2A).
[0007] Automated 2A peptides were first identified as originating from foot-and-mouth disease virus (FMDV). FMDV belongs to the genus Foot-and-Mouth Virus in the family Small RNA Viridae. The high-level structure that can be formed during the translation process of protease 2A encoded by the FMDV genome sterically interferes with the center of the ribosomal peptidyltransferase, preventing the formation of a normal peptide chain bond. However, the ribosome can simultaneously continue translating the downstream protein, thereby creating a proteolytic enzyme-like action that "cuts" the two proteins in a cis manner. Similar to FMDV, 2A peptides are also found in cardioviruses of the Picornaviridae family, Tiller's mouse encephalomyelin virus, equine rhinitis virus, and porcine Zieshen virus. Furthermore, similar gene sequences with the function of 2A peptides have been found in insect viruses, rotavirus type C, and trypanosomal repeat sequences. Automated processing sequences of 2A peptides or 2A-like peptides, similar to internal ribosome entry sites (IRESs), are frequently used in multi-gene expression to achieve the goal of independently expressing two or more non-fusioned foreign proteins. Compared to IRESs, 2A peptides or 2A-like peptides offer clear advantages in the construction of multi-gene expression vectors. For example, 2A peptides or 2A-like peptides are small and have a good balance of expression between upstream and downstream genes linked by the 2A element. This invention uses the automated processing peptide P2A to link three proteins, TH, AADC, and GCH1, to obtain the independent and efficient expression of these three proteins.
[0008] A viral vector genome comprising a gene sequence construct for the treatment of any of the above-mentioned central nervous system diseases, The aforementioned viral vector includes a lentiviral vector or an adeno-related viral vector.
[0009] A lentiviral vector system comprising a genome containing a gene sequence construct for the treatment of the above-mentioned central nervous system disease, and nucleotide sequences of one or more nucleotide sequences for encoding gag and pol proteins and other necessary viral packaging components.
[0010] A biological agent comprising any of the gene sequence constructs described above, said biological agent used for the treatment and / or prevention of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases. A biological preparation comprising any of the gene sequence constructs described above, wherein the biological preparation comprises a construct viral vector system comprising the gene sequence described above, and other necessary viral packaging components, and further formed by adding a pharmaceutically acceptable vector or diluent to the viral particles, and is used for the preparation of drugs for producing dopamine in the body, and for the treatment and / or prevention of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.
[0011] Specifically, a gene sequence construct comprising two or more selected nucleotide sequences from tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), and aromatic amino acid dopa decarboxylase (AADC), At least two of the aforementioned nucleotide sequences are joined by an automated processing unit (APU).
[0012] A gene sequence construct containing the nucleotide sequences of tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), and aromatic amino acid dopa decarboxylase (AADC) is selected. At least two of the nucleotide sequences are joined by an automatic processing unit (APU), and the gene sequence includes the following construction methods: TH , ,
[0013] CH1 -APU- AADC, TH -APU- CH1 -他の配列- AADC, TH -他の配列- CH1 -APU- AADC, TH -APU- AADC -APU- CH1, TH -他の配列- AADC -APU- CH1, TH -APU- AADC -他の配列- CH1, CH1 -APU- TH -APU- AADC, CH1 -APU- TH -他の配列- AADC;CH1 -他の配列- TH -APU -AADC, CH1 -APU- AADC -APU- TH, CH1 -APU- AADC -他の配列- TH, CH1 -他の配列- AADC -APU- TH, AADC -APU- TH -APU- CH1, AADC -APU- TH -他の配列- CH1, AADC -他の配列- TH -APU- CH1, AADC -APU- CH1 -APU- TH;AADC -APU- CH1 -他の配列- TH, AADC -他の配列- CH1 -APU- TH.
[0013] APU is an automatic processing unit, and the other sequences include linker peptide coding sequences (linker), internal ribosome entry sites (IRES), promoters, or inteins. The automated processing unit (APU) in the construct contains a 2A peptide or 2A-like peptide. The 2A peptide or 2A-like peptide in the gene sequence construct includes the 2A peptide (F2A) derived from foot-and-mouth disease virus, the 2A peptide (P2A) derived from porcine teschovirus, the 2A peptide (T2A) derived from insect virus, and the 2A peptide (E2A) derived from equine rhinitis virus.
[0014] When the gene sequence construct contains a promoter, the promoter is a constitutive promoter or a tissue-specific promoter. The constitutive promoter includes the CMV promoter, the phosphoglycerate kinase promoter, or the thymidine kinase promoter. The tissue-specific promoter includes the synapsin promoter, the CD68 promoter, the GFAP promoter, or other synthetic promoters.
[0015] Compared with the prior art, the present invention has the following advantages: 1. The present invention provides a new method for binding dopamine synthesis genes. Experimental studies of the present invention show that this method can improve the balance of target protein expression, increase the synthesis levels of dopamine and its metabolites, and improve the therapeutic effect of anti-Parkinson's disease. 2. The present invention first determines the expression of binding each protein using the self-processing peptide of P2A, and finally, it can generate tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid decarboxylase (AADC), and nerve growth factor with stable expression and independent functions, and provide a new poly-Si for the treatment and / or prevention of Parkinson's disease and other neurodegenerative diseases.
Brief Description of the Drawings
[0016] To more clearly illustrate embodiments of the present invention or technical solutions in the prior art, the following is a brief introduction of the drawings necessary for describing the embodiments or the prior art. Clearly, the drawings described below are only a few embodiments of the present invention, and those skilled in the art can obtain other drawings based on these without any creative effort.
[0017] [Figure 1] This is a schematic diagram of the gene sequence construct for Parkinson's disease gene therapy according to the present invention. [Figure 2] This is a schematic diagram of the structure of the construct of the present invention. [Figure 3] This figure shows the results of Western blot detection of aromatic amino acid dopa decarboxylase (AADC), GTP-cyclohydrolase I (GCH1), and tyrosine hydroxylase (TH) proteins after transduction of 293T cells. [Figure 4] This figure shows the detection of aromatic amino acid dopa decarboxylase (AADC), GTP-cyclohydrolase I (GCH1), and tyrosine hydroxylase (TH) proteins by Western blot after transduction of SH-SY5Y cells. [Figure 5] This figure shows the results of HPLC detection of dopamine DA production after the virus was transduced into SH-SY5Y cells.
[0018] Here, Figure 1 shows a coding sequence expressing aromatic amino acid dopa decarboxylase (AADC), GTP-cyclohydrolase I (GCH1), and tyrosine hydroxylase (TH). These proteins are linked together by an autoprocessing peptide P2A. The gene is transcribed and translated, and after processing with the autoprocessing peptide, independent aromatic amino acid dopa decarboxylase (AADC-P2A), GTP-cyclohydrolase I (GCH1-P2A), and tyrosine hydroxylase (TH) can be produced, with P2A being the 2A autoprocessing peptide of porcine zieshen virus.
[0019] In Figure 2, AADC is aromatic amino acid dopa decarboxylase, GCH1 is GTP-cyclohydrolase I, TH is tyrosine hydroxylase, P2A is 2A-treated peptide of porcine zysen virus, and synapsin, CMV, SV40, and PGK are all promoters.
[0020] In Figure 3, the blank represents a transduction group without virus, the GFP:CMV promoter-EGFP virus transduction group, PD-1 represents a Synapsin promoter-AADC-P2A-GCH1-P2A-TH virus transduction group, PD-2 represents a CMV promoter-AADC-P2A-GCH1-P2A-TH virus transduction group, the P:CMV promoter-AADC-SV40 promoter-TH-PGK promoter-GCH1 virus transduction group, Endo-TH represents endogenous TH from the cell, and Exo-TH represents TH with only the catalytic domain exogenously overexpressed.
[0021] In Figure 4, the blank represents the transduction group without virus, the GFP:CMV promoter-EGFP virus transduction group, PD-1 represents the Synapsin promoter-AADC-P2A-GCH1-P2A-TH virus transduction group, PD-2 represents the CMV promoter-AADC-P2A-GCH1-P2A-TH virus transduction group, the P:CMV promoter-AADC-SV40 promoter-TH-PGK promoter-GCH1 virus transduction group, Endo-TH represents intracellular TH, and Exo-TH represents exogenously overexpressed TH containing only the catalytic domain.
[0022] In Figure 5, GFP is the GFP virus transduction group, and PD-2 is the CMV promoter-AADC-P2A-GCH1-P2A-TH virus transduction group. [Modes for carrying out the invention]
[0023] The present invention will be described in more detail below with reference to examples. The following examples are for interpreting the present invention, but the present invention is not limited to the following examples.
[0024] Examples: 1. Construction of various constructs as shown in Figure 2: The KL0039 vector is artificially synthesized and uses the CMV enhancer-synapsin promoter-AADC-P2A-GCH1-P2A-TH and AADC-SV40 promoter-TH-PGK promoter-GCH1 sequences (where TH is a cleaved TH). The CMV enhancer-synapsin promoter-AADC-P2A-GCH1-P2A-TH sequence is conjugated to the pUC57 vector (pUC57-synapsin-AGT). The KL0039 vector is a lentiviral transfer vector selected from existing lentiviral vectors or, if necessary, lentiviral vectors that have been partially modified.
[0025] 1. Construction of the PD1 vector Using the KL0039 vector as a template, the sequence between WPRE and cPPT was amplified using Age-F + Sal-R, and the PCR product was recovered and purified by electrophoresis. The primer sequences used were Age-F (i.e., CTGAGTGCCATTGGATGA caatcaacctctggattaca) and Sal-R (i.e., gattactattaataactactcacgcatgctcttctcca). Simultaneously, the pUC57-synapsin-AGT plasmid was enzymatically digested with AgeI and SalI to recover a 4.1kb band. The recovered and purified PCR product and the enzymatically digested synapsin-AGT fragment were then conjugated via T4 DNA ligase, and DH5α-competent cells were transformed. Several single clones were selected for PCR identification, and positive clones were confirmed by sequencing.
[0026] 2. Construction of the PD2 vector Using the KL0039 vector as a template, the CMV promoter sequence is amplified using primers SnaBI-F (TCAGtacgtattagtcatcgctat) and SpeI-R (CGATactagtgagctctgcttatataga). The PCR product (245 bp) is recovered by electrophoresis and purified. The CMV promoter and pUC57-synapsin-AGT plasmid are simultaneously double-enzyme digested with SnaBI and SpeI. The CMV promoter and pUC57-AGT fragments are recovered and purified, respectively, and then ligated with T4 DNA ligase before transforming DH5α-competent cells. Monoclonal transformants are selected for PCR identification. Positive clones are confirmed by sequencing. These positive clones are named the pUC57-CMV-AGT plasmid. Next, using the KL0039 vector as a template, the sequence between WPRE and cPPT is amplified using Age-F+Sal-R. The PCR product is recovered by electrophoresis and purified. The PCR product and pUC57-CMV-AGT plasmid were simultaneously double-enzyme digested with AgeI and SalI. The PCR product and CMV-AGT fragments were recovered by electrophoresis and purified. After conjugation with T4 DNA ligase, DH5α-competent cells were transformed. Monoclonal transformants were selected for PCR identification. Positive clones were confirmed by sequencing.
[0027] 3. Vector construction: Replace the AGT sequence of the PD2 vector with the sequence AADC-SV40 promoter-TH-PGK promoter-GCH1.
[0028] 4. The GFP vector clones the EGFP sequence and replaces the AGT sequence in the PD2 vector.
[0029] II. Evaluate the differences in target protein expression in different constructs after transduction of 293T and SH-SY5Y cells.
[0030] 293T cell lines were rapidly transfected with a lentivirus 4 plasmid system, and lentiviruses GFP (CMV promoter-EGFP), PD1 (synapsin promoter-AGT), and PD2 (CMV promoter-AGT), as well as a positive control virus P (CMV promoter-AADC-SV40 promoter-TH-PGK promoter-GCH1), were packaged. The initial viruses were purified, concentrated, and diluted, and transduced into 293T cells. The titration concentration was measured by RT-PCR (WPRE / ALB), and the titration concentrations for all constructs were similar, with a titration concentration range of 3.4E+09 TU / ml to +8.74E+09 TU / ml.
[0031] To study the expression levels of target proteins, 293T cells were transduced with a viral MOI=10 for each group, and SH-SY5Y cells were transduced with an MOI=20. After 72 hours of transduction, cell lysates were collected for Western blot of AADC, GCH1, and TH. The results show that in 293T cells, low levels of TH were detected compared to endogenous proteins, but AADC and GCH1 were not detected. All proteins were as predicted. Compared to the virus-free transduction blank and the GFP viral transduction control, the highest levels of expression for all three proteins originated from the PD2 viral vector, with the AADC level being the highest for the P viral vector, while the other two proteins, GCH1 and TH, were virtually undetectable. In the case of the PD1 viral vector, its promoter is the neuron-specific promoter Synapsin, which is as expected, and none of the three target proteins are expressed in 293T cells (Figure 3). Furthermore, we detected the expression of target proteins from three different constructs in the neuronal cells SH-SY5Y. Both endogenous proteins TH and AADC were expressed, but GCH1 was not detected, and the molecular weights of all proteins were the same as predicted. Consistent with the results from 293T cells, and compared to the virus-free transduction blank and the GFP virus transduction control, the highest levels of expression for all three proteins still originated from the PD2 viral vector, with the AADC level being the highest from the P viral vector, while the other two proteins, GCH1 and TH, were still virtually undetectable. In the case of the PD1 viral vector, only small amounts of AADC and TH expression were observed, and GCH1 was virtually undetectable (Figure 4).
[0032] 3. Evaluate the differences in catecholamine production between different constructs after transduction of SH-SY5Y cells.
[0033] In neurons, dopamine (DA) is primarily converted to dihydroxyphenylacetic acid (DOPAC) by monoamine oxidase (MAO). Using lentiviral vectors, two types of cells, SHSY5Y and 293T, are transduced, and the amount of dopamine produced in the supernatant of the transduced cells is detected using mass spectrometry. After the virus is transduced into SH-SY5Y cells, the culture medium is changed overnight, and the culture is continued until day 3. The cell culture medium is collected, centrifuged at 4500 rpm for 5 minutes, and the culture supernatant is transferred to a 1.5 mL centrifuge tube and stored in a refrigerator at -80°C for detection. After the virus is transduced into SH-SY5Y cells, the culture medium is changed overnight, and after 2 days of culture, the cells are subcultured at 1:10, and culture is continued for 2 days. Then the medium is changed to fresh medium containing 10 mM L-Tyrosine, and the culture is continued until the next morning. The culture medium is collected, centrifuged at 4500 rpm for 5 minutes, and the culture supernatant is transferred to a 1.5 mL centrifuge tube and stored in a refrigerator at -80°C for detection.
[0034] The method for detecting dopamine content in a sample using mass spectrometry involves taking 500 μL of cell culture medium, adding an appropriate amount of internal standard, diluting and mixing with 1 mL of 50 mM ammonium acetate as a sample loading solution, activating with methanol, washing with 20 mM ammonium acetate and acetonitrile:isopropanol (1:1), aspirating and drying the cartridge, then eluting with 2% formate acetonitrile solution, drying under nitrogen, dissolving the residue in 100 μL of 0.1% FA, centrifuging at 15000 r / min for 5 min, taking the supernatant, and analyzing it with a machine (Angilent 1290UPLC-6470MS / MS detection system).
[0035] The results are shown in Figure 5, where 293T cells and SH-SY5Y cells transduced with the KL-PD2 lentiviral vector show a significant increase in dopamine production in the cell supernatant because the three dopamine synthetases are effectively and uniformly expressed.
[0036] It should be noted that in the specific examples described herein, the names of various substances or vectors may differ. All equivalent or simple modifications made in accordance with the structure and principles described in the patent concept of the present invention are all within the scope of the patent protection of the present invention. Those skilled in the art can make various modifications or additions to the specific examples described, or substitute them in similar ways, but as long as they do not deviate from the structure of the present invention or exceed the scope defined by the claims of this invention, they should all be within the scope of the protection of the present invention.
Claims
1. A gene sequence construct for treating a central nervous system disease, comprising: The construct comprises a plurality of nucleotide sequences related to the treatment of a central nervous system disorder, the plurality of nucleotide sequences includes a nucleotide sequence of a tyrosine hydroxylase (TH), a nucleotide sequence of a GTP-cyclohydrolase I (GCH1), and a nucleotide sequence of an aromatic amino acid decarboxylase (AADC); the TH, GCH1 and AADC nucleotide sequences are linked by a nucleotide sequence encoding an automatic processing unit (APU) comprising a 2A peptide; and The construct comprises a constitutive promoter. A gene sequence construct for treating a central nervous system disease, comprising:
2. The gene sequence construct for treating central nervous system diseases as described in claim 1, characterized in that the 2A peptide comprises a 2A peptide derived from foot-and-mouth disease virus (F2A), a 2A peptide derived from porcine teschovirus (P2A), a 2A peptide derived from an insect virus (T2A), or a 2A peptide derived from equine rhinitis virus (E2A).
3. The gene sequence construct for treating a central nervous system disease according to claim 1, further comprising a nucleotide sequence for a nervous system growth factor.
4. The gene sequence construct for treating central nervous system diseases according to claim 3, characterized in that the nervous system growth factor comprises nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), neurotrophic factor-4 / 5 (NT-4 / 5), neurotrophic factor-6 (NT-6), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), or GDNF molecule family.
5. 5. The gene sequence construct for the treatment of central nervous system diseases according to claim 4, wherein said GDNF family of molecules comprises naturally occurring analogues of GDNF, neurturin, persephin, or artemin.
6. A viral vector genome comprising a gene sequence construct for the treatment of a central nervous system disease according to any one of claims 1 to 5, The viral vector comprises a lentiviral vector or an adeno-associated viral vector. The viral vector genome.
7. A lentiviral vector system comprising a gene sequence construct for the treatment of a central nervous system disease according to any one of claims 1 to 5.
8. A biological preparation comprising a gene sequence construct according to any one of claims 1 to 5.
9. A gene sequence construct according to any one of claims 1 to 5, a viral vector genome according to claim 6, a lentiviral vector system according to claim 7 or a biological preparation according to claim 8 for use in the treatment and / or prevention of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.
